Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) was the recipient of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 24,900 shares, an increase of 6.4% from the February 13th total of 23,400 shares. Based on an average daily trading volume, of 5,800 shares, the days-to-cover ratio is currently 4.3 days. Approximately 0.5% of the shares of the company are short sold.

Institutional Trading of Anebulo Pharmaceuticals

A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. Herr Investment Group LLC purchased a new stake in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 29,644 shares of the company’s stock, valued at approximately $72,000. Herr Investment Group LLC owned 0.12% of Anebulo Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 26.70% of the company’s stock.

Anebulo Pharmaceuticals Trading Up 14.8 %

NASDAQ ANEB opened at $2.87 on Friday. The stock has a 50-day moving average of $2.90 and a 200-day moving average of $2.82. The firm has a market cap of $73.56 million, a PE ratio of -6.52 and a beta of -1.43. Anebulo Pharmaceuticals has a 1-year low of $1.77 and a 1-year high of $7.73.

Analyst Upgrades and Downgrades

Separately, Benchmark reduced their target price on Anebulo Pharmaceuticals from $10.00 to $8.00 and set a “speculative buy” rating for the company in a research report on Tuesday, February 14th.

Anebulo Pharmaceuticals Company Profile

(Get Rating)

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.